Immunic is a biotechnology business based in the US. Immunic shares (IMUX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.14 – an increase of 6.54% over the previous week. Immunic employs 85 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.14 |
|---|---|
| 52-week range | $0.97 - $2.11 |
| 50-day moving average | $1.42 |
| 200-day moving average | $1.34 |
| Wall St. target price | $13.25 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.23 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.18 from 2024-11-25
| 1 week (2024-11-20) | 10.28% |
|---|---|
| 1 month (2024-10-25) | -15.11% |
| 3 months (2024-08-27) | -16.01% |
| 6 months (2024-05-24) | -5.60% |
| 1 year (2023-11-27) | 0.85% |
|---|---|
| 2 years (2022-11-25) | -11.94% |
| 3 years (2021-11-26) | 8.61 |
| 5 years (2019-11-27) | 6.99 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -90.9% |
| Return on equity TTM | -216.24% |
| Profit margin | 0% |
| Book value | $0.46 |
| Market Capitalization | $100 million |
TTM: trailing 12 months
We're not expecting Immunic to pay a dividend over the next 12 months.
Immunic's shares were split on a 1:40 basis on 14 April 2019 . So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Immunic shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for Immunic shares which in turn could have impacted Immunic's share price.
Over the last 12 months, Immunic's shares have ranged in value from as little as $0.97 up to $2.11. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Immunic's is 1.883. This would suggest that Immunic's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Immunic, Inc. , a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York. .
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.